Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06385301
Other study ID # Lung_disease_6MWD_SOT
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date November 2025

Study information

Verified date April 2024
Source University of Zurich
Contact Silvia Ulrich, Prof. Dr.
Phone +41442552220
Email silvia.ulrich@usz.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators aim to study the effect of SOT in subjects with chronic lung disease in submaximal exercise.


Description:

Participants with lung disease who live in Switzerland will have 6-minute walk distance (6MWD) test with and without SOT at approximately 3l/min via nasal cannula according to a randomized cross-over design. The trial aims to test that the 6MWD with SOT is non-inferior to a 6MWD in the same participant under ambient air. Our effect size was estimated with a difference of less or equal to 35m compared under SOT compared to ambient air.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 14
Est. completion date November 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Minimum 18 years of age - Written informed consent - Patients with diagnosed chronic lung disease - Former desaturation under exercise defined as Spo2-decrease >3%- Page 3 of 4 - Treated with a stable drug therapy (with no changes for at least 14 days prior to screening) Exclusion Criteria: - Severe hypoxemia needing supplemental oxygen therapy defined as (partial pressure of Oxygen (PaO2) < 6.9 KiloPascal (kPa) - Pregnancy - Unability or contraindications to undergo the investigated intervention - Unability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.

Study Design


Intervention

Other:
6-minute walk distance (6MWD) test on ambient air
6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards
6-minute walk distance test with supplemental oxygen (approximately 3l/min, nasal)
6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (approximately 3l/min, nasal)

Locations

Country Name City State
Switzerland University Hospital Zürich Zurich

Sponsors (1)

Lead Sponsor Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary 6-minute walk distance (6MWD) with supplemental oxygen therapy (SOT) vs. ambient air Change in 6MWD in meter between SOT via nasal cannula vs. ambient air after 6 minutes
Secondary SpO2 at rest and peak 6MWD with SOT vs. ambient air Change of the arterial oxygen saturation by pulse oximetry (SpO2) at rest and at peak 6MWD with SOT vs. ambient air after 6 minutes
Secondary Heart rate at rest and peak 6MWD with SOT vs. ambient air Change of heart rate (bpm) at rest and at peak 6MWD with SOT vs. ambient air after 6 minutes
Secondary Borg dyspnea scale at rest and peak 6MWD with SOT vs. ambient air Change of Borg dyspnea scale at rest and at peak 6MWD with SOT vs. ambient air 6 minutes
Secondary Borg leg fatigue scale at rest and peak 6MWD with SOT vs. ambient air Change of Borg leg fatigue scale at rest and at peak 6MWD with SOT vs. ambient air after 6 minutes
Secondary Blood pressure at rest and peak 6MWD with SOT vs. ambient air Change of Blood pressure (mmHg) at rest and at peak 6MWD with SOT vs. ambient air after 6 minutes
See also
  Status Clinical Trial Phase
Completed NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT00281216 - Innate and Adaptive Immunity in Individuals Experiencing Chronic Obstructive Pulmonary Disease Exacerbations N/A
Completed NCT00281242 - Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease N/A
Completed NCT00281229 - T Lymphocyte Cells in Individuals Experiencing an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Completed NCT00159341 - Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 1
Completed NCT00281203 - Comparison of Alveolar Macrophages in Healthy Individuals Versus Individuals With COPD N/A
Completed NCT00281190 - Comparison of Alveolar Macrophages in Individuals With COPD Versus Smokers With Normal Pulmonary Function N/A
Completed NCT00069823 - Study of Acid Reflux in Asthma Phase 3
Completed NCT00006513 - Assessing the Occupation Burden in COPD N/A
Completed NCT00006306 - Effects of Chronic Ozone Exposure on Lung Function N/A
Completed NCT00000621 - Feasibility of Retinoic Acid Treatment in Emphysema (FORTE) Phase 2
Completed NCT00000569 - Lung Health Study II Phase 3
Completed NCT00005425 - Statistical Analysis of Vlagtwedde-Vlaardingen Data Set N/A
Completed NCT00005720 - Lay-Led Smoking Cessation Approach for Southeast Asian Men N/A
Completed NCT00000568 - Lung Health Study (LHS) I and III Phase 3
Completed NCT00005281 - Early Risk Predictors For Chronic Pulmonary Disease N/A
Not yet recruiting NCT05286918 - Antibiotic Stewardship in AECOPD Through CRP-Guided Management N/A
Recruiting NCT05565872 - Effects of Supervision During a Community-based Exercise Intervention (Urban Training) in Patients With COPD N/A
Not yet recruiting NCT02928666 - Integration of Guidelines for Comorbidities N/A
Completed NCT02306473 - The Leaky Lung Test Early Phase 1